| Code | CSB-RA011587MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Ustekinumab-kfce, targeting IL12B (interleukin-12 subunit beta), also known as the p40 subunit. IL12B is a shared component of both interleukin-12 (IL-12) and interleukin-23 (IL-23), two critical cytokines that regulate T-cell differentiation and inflammatory responses. By binding to the p40 subunit, this antibody effectively neutralizes both IL-12 and IL-23 signaling pathways. These cytokines play central roles in the pathogenesis of various immune-mediated inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and other autoimmune disorders characterized by aberrant Th1 and Th17 cell responses.
Ustekinumab-kfce is an FDA-approved therapeutic antibody used clinically for treating moderate-to-severe plaque psoriasis and inflammatory bowel disease. This research-grade biosimilar provides investigators with a valuable tool for studying IL-12/IL-23 signaling mechanisms, evaluating inflammatory pathway modulation, investigating autoimmune disease models, and exploring novel therapeutic strategies targeting these cytokine networks in preclinical research settings.
There are currently no reviews for this product.